 announces the membership of the Belfast facility within the UK Respiratory Therapeutic Capability Cluster. Celerion will work with key decision makers and thought leaders in the UK to develop and execute Phase I and IIa studies with targeted patient populations. 

The UK Respiratory Therapeutic Capability Cluster is a cooperative of clinicians and scientists whose aim is to improve the speed of developing innovative therapies for respiratory diseases by working in collaboration with research groups of the pharmaceutical industry.

 The collaboration with the UK Respiratory Therapeutic Capability Cluster provides access to patients suffering from asthma, COPD, cystic fibrosis, bronchiectasis, and interstitial lung disease. Celerion has access to laboratory capabilities (flow cytometry, flow cytometric cell sorting, microbiology, 16S, deep sequencing, MLST, transcriptomics) as well as lung imaging techniques (CT acquisition of images, dedicated MRI time, advanced CT analysis capabilities and MRI acquisition of images).